The advice supports MAA’s ongoing development efforts and provides regulatory clarity for advancing the program in Canada. Importantly, the feedback from Health Canada is consistent with guidance previously received from the U.S. Food and Drug Administration (FDA) and the Federal Institute for Drugs and Medical Devices (BfArM) in Germany, further validating the Company’s development strategy and the scientific strength of its NanoCOnt™ platform.

“We are grateful for Health Canada’s constructive guidance,” said Dr. Anjani Jha, CEO of MAA Laboratories. “The alignment we have now achieved across U.S., European, and Canadian regulators provides strong validation for our regulatory and clinical approach and reinforces our confidence in the potential of our nanoparticle-based therapies.”

MAA Laboratories remains committed to delivering differentiated therapies that improve patient outcomes through enhanced drug delivery, tolerability, and systemic performance. The Company looks forward to advancing its broader pipeline across global markets.

For press and other inquiries, please contact:
Email: info@maalaboratories.com
Phone: +1 (919)271.7868